Inhibition of Oestradiol-induced Prolactin Release in a Dual-Cannulated Ovariectomized Rat Model by Carmoxirole, a Peripherally Restricted Dopamine Agonist

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 6, 2012, Pages 411-416

  Brott, David A ^a   Werkheiser, Jennifer L ^a   Campbell, Pam ^a   Bentley, Patricia ^a   Andersson, Håkan H A S ^b   Stewart, Jane ^a   Huby, Russell ^a   Altekar, Maneesha ^a   Kinter, Lewis B ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CARMOXIROLE; ESTRADIOL; ESTROGEN; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANNULATION; CONTROLLED STUDY; FEMALE; HORMONE INHIBITION; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROLACTIN RELEASE; RAT;

ANIMALS; BROMOCRIPTINE; DOPAMINE AGONISTS; ESTRADIOL; ESTRADIOL ANTAGONISTS; FEMALE; INDOLES; OVARIECTOMY; PIPERAZINES; PROLACTIN; PYRIDINES; RATS; RATS, WISTAR; STIMULATION, CHEMICAL;

RATTUS;

EID: 84869177789     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00918.x     Document Type: Article

References (35)

1. Hargreaves A, Harleman J. Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia. J Appl Toxicol 2011;31:599-607.
2. Bussiere JL, Exon JH, Mather GG. Effects of bromocriptine treatment on immune responses and 3-methylcholanthrene-induced tumorigenesis in rats. Immunopharmacol Immunotoxicol 1991;13:47-64.
3. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev 2008;29:1-41.
4. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-631.
5. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997;19:103-13.
6. Saiardi A, Bozzi Y, Baik JH, Borrelli E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 1997;19:115-26.
7. Berry SA, Gudelsky GA. D1 receptors function to inhibit the activation of tuberoinfundibular dopamine neurons. J Pharmacol Exp Ther 1990;254:677-82.
8. Berry SA, Gudelsky GA. Effect of D2 dopamine agonists on tuberoinfundibular dopamine neurons. Neuropharmacology 1991;30:961-5.
9. Hoeffler JP, Boockfor FR, Frawley LS. Ontogeny of prolactin cells in neonatal rats: initial prolactin secretors also release growth hormone. Endocrinology 1985;117:187-95.
10. Arita J, Kojima Y, Kimura F. Identification by the sequential cell immunoblot assay of a subpopulation of rat dopamine-unresponsive lactotrophs. Endocrinology 1991;128:1887-94.
11. Leite CM, Szawka RE, Anselmo-Franci JA. Alpha-oestrogen and progestin receptor expression in the hypothalamus and preoptic area dopaminergic neurons during oestrus in cycling rats. J Neuroendocrinol 2008;20:110-9.
12. Sellix MT, Egli M, Henderson RP, Freeman ME. Ovarian steroid hormones modulate circadian rhythms of neuroendocrine dopaminergic neuronal activity. Brain Res 2004;1005:164-81.
13. Eaton MJ, Gopalan C, Kim E, Lookingland KJ, Moore KE. Comparison of the effects of the dopamine D2 agonist quinelorane on tuberoinfundibular dopaminergic neuronal activity in male and female rats. Brain Res 1993;629:53-8.
14. Caligaris L, Astrada JJ, Taleisnik S. Oestrogen and progesterone influence on the release of prolactin in ovariectomized rats. J Endocrinol 1974;60:205-15.
15. Hallstrom IP, Liao DZ, Assefaw-Redda Y, Ohlson LC, Sahlin L, Eneroth P et al. Role of the pituitary in tumor promotion with ethinyl estradiol in rat liver. Hepatology 1996;24:849-54.
16. Sumi C, Yokoro K, Matsushima R. Suppression of diethylstilbesterol and N-nitrosobutylurea-induced mammary and pituitary tumorigenesis in rats by prolonged treatment with 2-bromoergocryptine. Cancer Res 1983;43:4781-5.
17. Takahashi S, Okazaki K, Kawashima S. Mitotic activity of prolactin cells in the pituitary glands of male and female rats of different ages. Cell Tissue Res 1984;235:497-502.
18. Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J Neurol 2003;250:90-6.
19. Nagasawa H, Morii S. Inhibition by early treatment with bromocriptine of spontaneous mammary tumour development in rats with no side-effects. Acta Endocrinol 1982;101:51-5.
20. Yoshida M, Watanabe G, Suzuki T, Inoue K, Takahashi M, Maekawa A et al. Long-term treatment with bromocriptine inhibits endometrial adenocarcinoma development in rats. J Reprod Dev 2009;55:105-9.
21. Welsch CW, Goodrich-Smith M, Brown CK, Wilson M. Inhibition of mammary tumorigenesis in GR mice with 2-bromo-alpha-ergocryptine. Int J Cancer 1979;24:92-6.
22. Welsch CW, Lambrecht LK, Hassett CC. Suppression of mammary tumorigenesis in C3H/He mice by ovariectomy or treatment with 2-bromo-alpha-ergocryptine: a comparison. J Natl Cancer Inst 1977;58:1135-8.
23. Murai I, Ben-Jonathan N. Acute stimulation of prolactin release by estradiol: mediation by the posterior pituitary. Endocrinology 1990;126:3179-84.
24. Valente D, Delaforge M, Urien S, Guivarc'h D, Vienet R, Grognet JM et al. Metabolite involvement in bromocriptine-induced prolactin inhibition in rats. J Pharmacol Exp Ther 1997;282:1418-24.
25. España RA, Roberts DC, Jones SR. Short-acting cocaine and long-acting GBR-12909 both elicit rapid dopamine uptake inhibition following intravenous delivery. Neuroscience 2008;155:250-7.
26. Marchese G, Ruiu S, Casti P, Bartholini F, Saba P, Gessa GL et al. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. Eur J Pharmacol 2002;447:109-14.
27. Brann DW, Putnam CD, Mahesh VB. Antagonism of estrogen-induced prolactin release by dihydrotestosterone. Biol Reprod 1989;40:1201-7.
28. DeMaria J, Nagy G, Lerant A, Fekete M, Levenson C, Freeman M. Dopamine transporters participate in the physiological regulation of prolactin. Endocrinology 2000;141:366-74.
29. Ribeiro MF, Spritzer PM, Barbosa-Coutinho LM, Oliveira MC, Pavanato MA, Silva IS et al. Effects of bromocriptine on serum prolactin levels, pituitary weight and immunoreactive prolactin cells in estradiol-treated ovariectomized rats: an experimental model of estrogen-dependent hyperprolactinemia. Braz J Med Biol Res 1997;30:113-7.
30. Denef C, Manet D, Dewals R. Dopaminergic stimulation of prolactin release. Nature 1980;285:243-6.
31. Kramer IM, Hopkins CR. Studies on the kinetics of dopamine-regulated prolactin secretion. Mol Cell Endocrinol 1982;28:191-8.
32. Burris TP, Stringer LC, Freeman ME. Pharmacologic evidence that a D2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland. Neuroendocrinology 1991;54:175-83.
33. Arey BJ, Burris TP, Basco P, Freeman ME. Infusion of dopamine at low concentrations stimulates the release of prolactin from alpha-methyl-p-tyrosine-treated rats. Proc Soc Exp Biol Med 1993;203:60-3.
34. Close FT, Freeman ME. Effects of ovarian steroid hormones on dopamine-controlled prolactin secretory responses in vitro. Neuroendocrinology 1997;65:430-5.
35. Martinez de la Escalera G, Weiner RI. Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion. Endocr Rev 1992;13:241-55.